Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Losartan Potassium NDC 53002-1638 by Rpk Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label Image - lbl530021638
Not available.*
Label Image - lbl530021643
lbl530022624
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
The text mentions the names of two medications, Atenolol and Losartan Potassium, and a statistical result indicating a 13% reduction in adjusted risk for a primary endpoint based on a study. The study was conducted for a period of 66 months with measurements taken at various points along the way.*
Figure 2 - spl image3 figure2
This document appears to be a comparison between two medications, Atenolol and Losartan Potassium. The adjusted risk reduction for Losartan Potassium is listed as 25% with a p-value of 0.001. The text also lists the percentage of patients with fatal/non-fatal stroke at various study months.*
Figure 3 - spl image4 figure3
The text describes a table (Figure 3) that shows the primary endpoint events within demographic subgroups for a study that compared the effectiveness of Losartan Potassium and Atenolol in preventing stroke. The subgroups include age, gender, race, ISH, diabetes, and history of CVD. The table presents the number of events and rates for each subgroup, as well as hazard ratios with their corresponding 95% confidence intervals. The text also indicates that the symbols in the table are proportional to sample size and provides a note about the adjustment for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - spl image5 figure4
This is a graph that shows the percentage of patients with an event over the course of 48 months while taking either Losartan Potassium or a placebo. The Risk Reduction is 16.1% with a p-value of 0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.